Home/Products /gemcitabine-200mg-injection

GEMTYLE 200 Injection: Gemcitabine 2000 mg

Name: GEMTYLE 2000: Gemcitabine 2000 mg Injection | Premium High-Dose Oncology PCD Franchise
Brand: Gemtyle 200 Injection
Rating: 4.8 (150 reviews)

Clinical Necessity: High-Dose Gemcitabine for Aggressive Cancers

Gemcitabine: Foundation of Combination Chemotherapy Protocols

Mechanism of Action: S-Phase Specific DNA Synthesis Inhibition

Targeting Institutional Supply and Bulk Oncology Tenders

High-Margin Opportunity: GEMTYLE 2000 PCD Pharma Franchise

Therapeutic

ENDOCRINOLOGY and Hormonal range

Gastroenterology

General and OTC medicines

Gynecology and Fertility

Hepatology

Hypertension/ Blood Pressure

Nutraceuticals, Multivitamins and Multiminerals

Sedative or Antianxiety

Stimulant

Urology

GEMTYLE 200 Gemcitabine 2000 mg Injection vial in hospital setting

High-dose chemotherapy Gemcitabine for cancer treatment

Packaging of Gemcitabine 2000 mg for institutional supply

PCD Pharma franchise injectable oncology product

Gemcitabine antimetabolite chemotherapy vial

Gemtyle 200 Injection

Composition : Gemcitabine 200mg Injection

Dosage Form : Injection

Packaging Type : Vial

Packaging : 200mg

Price : ₹1/-

Please Contact For Best Price

GEMTYLE 200 Injection (Gemcitabine 2000 mg) provides a critical, high-volume dosage form of the established antimetabolite chemotherapy agent, Gemcitabine. It is a fundamental component of treatment regimens for several solid tumors, including: Pancreatic Cancer (often first-line), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, and Metastatic Breast Cancer.

The drug exerts its powerful effect by acting as a deoxycytidine analog, which is metabolized inside cancer cells into active diphosphate and triphosphate forms. These metabolites efficiently inhibit DNA synthesis and repair, leading to apoptotic cell death. The 2000 mg presentation is particularly optimized for institutional and hospital settings that require larger volumes for patient protocols, often involving combination therapies.

The demand for Gemcitabine is inelastic in the oncology sector, making GEMTYLE 200 a strategic, high-turnover product. We offer a specialized PCD Pharma Franchise opportunity with Monopoly Rights for this high-dose injectable. Partnering with us grants you access to institutional marketing materials, competitive tender support, and excellent profit margins in the rapidly expanding anti-cancer injectable market.

About the Product

May cause headache, muscle pain, nausea, abdominal discomfort, or mild liver enzyme elevation. Rarely, serious muscle problems (myopathy or rhabdomyolysis) may occur.

Primary hypercholesterolemia Mixed dyslipidemia Familial hypercholesterolemia Prevention of cardiovascular disease in high-risk patients

Take under medical supervision, preferably once daily, with or without food. Regular liver function and lipid profile monitoring is advised. Inform your doctor about any muscle pain, weakness, or pre-existing liver/kidney conditions. Avoid excessive alcohol intake.

Store in a cool, dry place below 25°C, protected from light and moisture. Keep out of reach of children.